CD207

Across TCGA pan-cancer cohorts, CD207 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD207 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD207 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CD207 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where CD207 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.797	0.350	.001	22	view →
PDAC	DFS	Quartile	All	0.849	0.686	.011	6	view →
UCEC	DFS	Median	III,IV	0.439	1.000	.027	4	view →
LSCC	DFS	Tertile	III,IV	1.000	0.774	.049	1	view →
HNSC	OS	Median	III,IV	0.948	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD207–LUAD (OS)

Open the LUAD breakdown →